the first-line management of advanced NSCLC. Future clinical developments of bevacizumab in NSCLC treatment will include the amalgamation of this agent with other targeted therapies in advanced disease and the integration of this agent into combined modality approaches for the treatment of early-stage and locally advanced disease. A randomized phase II study of Bevacizumab (7.5 mg/kg or 15 mg/kg) in combination with carboplatin and paclitaxel compared with Carboplatin plus Paclitaxel alone in 99 patients with stage IIIB or IV NSCLC was performed [13] . Response rates with the antibody administered at 15 mg/kg were about 10% higher (31.5%, 28.1%, and 18.8% in the high-dose antibody group, the low-dose antibody group, and the chemotherapy-alone group, respectively), and the time to tumour progression was approximately 3 months longer (7.4, 4.3, and 4.2 months, respectively). A trend toward a longer survival time was also reported (17.7, 11.6 , and 14.9 months, respectively). Based on the promising results of the above-mentioned phase II randomized trial 13 , the Eastern Cooperative Oncology Group (ECOG) conducted a randomized study (E4599) in which 878 patients with recurrent or advanced nonsquamous NSCLC were assigned to either chemotherapy with paclitaxel and carboplatin alone (n=444) or paclitaxel and carboplatin plus bevacizumab (n= 434) 14 . Patients with squamous cell tumours, brain metastases, clinically significant haemoptysis, or inadequate organ function or performance status (ECOG performance status [PS] score>1) were excluded. Squamous histology was excluded because of the risk for grade 5 haemoptysis reported in the previous phase II randomized study. Patients were randomized to receive paclitaxel (200 mg/m 2 ) and carboplatin (to an area under the concentrationtime curve of 6) plus bevacizumab (15 mg/kg) on day 1 every 3 weeks or the same chemotherapy regimen alone. Patients in the bevacizumab arm continued bevacizumab after six cycles until progressive disease or intolerable toxicity. The primary endpoint was overall survival. The median survival time was 12.3 months in the group assigned to chemotherapy plus bevacizumab, compared with 10.3 months in the chemotherapy-alone group (hazard ratio [HR] for death, 0.79; p=.003). The median progression-free survival times in the two groups were 6.2 and 4.5 months, respectively (HR for disease progression, 0.66; p<.001), with stage patients, traditional chemotherapy has lately produced promising results as an adjuvant approach 7, 8 , and there were some progress made in the treatment of locally advanced and advanced disease 9, 10 , treatment outcomes for NSCLC are still to be considered substandard. The singling out of numerous molecular targets for NSCLC treatment has been established because of the Advances in the knowledge of tumour biology and mechanisms of oncogenesis. Some contemplation can currently be drawn according to the first generation of clinical trials of targeted agents in NSCLC treatment which has been concluded. As yet, negative results are more commonly reported than positive ones because only few of these new agents can offer hope of a substantial impact on the natural history of the disease. One of the most concerned targeted approaches most widely studied in the treatment of NSCLC is the inhibition of angiogenesis 11, 12 because it is exceedingly angiogenesis driven disease. Among angiogenesis inhibitors, the antivascular endothelial growth factor (VEGF) monoclonal antibody (mAb) Bevacizumab (Avastin®; Genentech Inc., South San Francisco, CA) signifies the utmost prosperous targeted therapy which came up with the first evidence of improvement in treatment outcomes of chemotherapy with targeted therapies in the firstline treatment of advanced NSCLC. Bevacizumab, at this point in time, is the most promising targeted agent for the treatment of NSCLC on the basis of the results in first-line treatment, and its role in combination with other targeted agents or in other settings, such as second-line treatment of advanced NSCLC disease, early-stage disease (as adjuvant and neoadjuvant treatment), and locally advanced disease, must be defined. Bevacizumab, an antigrowth factor vascular endothelial growth factor (VEGF) recombinant humanized monoclonal antibody, is the antiangiogenic agent at the most progressive stage of development in the treatment of solid tumours and also in advanced NSCLC treatment. Bevacizumab, combined with platinumbased chemotherapy, has been demonstrated to improve efficacy outcomes over chemotherapy alone in the treatment of nonsquamous advanced NSCLC in two phase III randomized trials. These signify the first substantiation of development in treatment outcomes of chemotherapy with targeted therapies in survival times were 6.1, 6.7, and 6.5 months, respectively, for chemotherapy alone, chemotherapy plus bevacizumab 7.5 mg/kg, and chemotherapy plus bevacizumab 15 mg/kg (HR, 0.75; 95% confidence interval [CI], 0.62-0.90; p = .002 for bevacizumab 7.5 mg/kg and HR, 0.82; 95% CI, 0.68-0.98; p = .03 for bevacizumab 15 mg/kg). The response rate and response duration were also significantly greater with bevacizumab. Response rates were 20%, 34%, and 30%, respectively, for chemotherapy alone, chemotherapy plus bevacizumab 7.5 mg/kg, and chemotherapy plus bevacizumab 15 mg/kg. The response durations were 4.7, 6.1, and 6.1 months, respectively, for chemotherapy alone, chemotherapy plus bevacizumab 7.5 mg/kg, and chemotherapy plus bevacizumab 15 mg/kg. No difference according to gender was observed, minimizing the gender issue of the ECOG 4599 trial. Both doses of bevacizumab significantly improved the progression-free survival time and response rate over those seen with chemotherapy alone (cisplatin and gemcitabine), as observed in the earlier phase III trial E4599, against carboplatin and paclitaxel. No unexpected safety signals were detected in this trial, with grade 3 adverse events occurring in 75%, 76%, and 81% of the three treatment groups, respectively (chemotherapy alone, chemotherapy plus bevacizumab 7.5 mg/kg, and chemotherapy plus bevacizumab 15 mg/kg). Adverse events leading to death occurred in 4%, 4%, and 5% of the three groups, respectively; grade 3 haemoptysis occurred in <1%, 1.5%, and <1% and grade 3 hypertension occurred in 4%, 4%, and 5%, respectively.
Phase III randomized trials of bevacizumab plus chemotherapy in first-line treatment of advanced nonsquamous NSCLC Table I: corresponding response rates of 35% and 15% (p<.001). No difference among different subgroups of patients was found, except for gender. In fact, the median overall survival times in the paclitaxelcarboplatin group and the paclitaxel-carboplatinbevacizumab group were 8.7 and 11.7 months, respectively, among men and 13.1 and 13.3 months, respectively, among women. Possible explanations for this finding include imbalances between the two groups with respect to known or unknown baseline prognostic factors, imbalances in the use of secondand third-line therapies (men received more secondline chemotherapy), statistical chance, or a true sexbased difference. Although it has been postulated that baseline VEGF levels correlate with the clinical outcome of bevacizumab treatment, in this trial, baseline plasma VEGF levels did not correlate with survival. In summary, the rates of hypertension, proteinuria, bleeding, neutropenia, febrile neutropenia, thrombocytopenia, hyponatremia, rash, and headache were significantly higher in the paclitaxel-carboplatin-bevacizumab group than in the paclitaxel-carboplatin group (p<.05). This study represents the first evidence of superior efficacy of targeted therapy combined with chemotherapy over chemotherapy alone in the treatment of NSCLC.
Very recently, another randomized, placebocontrolled, phase III study (the Avastin (Bevacizumab) in Lung [AVAiL] trial) evaluated the addition of bevacizumab to chemotherapy (cisplatin plus gemcitabine) in the treatment of advanced NSCLC 15 compared two doses of bevacizumab plus cisplatin and gemcitabine with cisplatin and gemcitabine plus placebo. The primary endpoint was progression-free survival; secondary endpoints included overall survival, response rate, and safety. Eligibility criteria included, as in the ECOG trial, previously untreated advanced nonsquamous NSCLC patients with an ECOG PS score of 0-1 and no brain metastases. About 1,000 patients were randomized to receive cisplatin and gemcitabine every 3 weeks for up to six cycles plus bevacizumab, continued to progression, at 7.5 mg/kg every 3 weeks, or 15 mg/kg every 3 weeks, or placebo. The study was designed to include the number of patients required to observe a 30% reduction in the risk for a progressionfree survival event in the bevacizumab arms compared with control, using a two-sided log-rank test with 80% power.The median progression-free > > > up. At the time of the OS analysis, PFS was significantly longer in all bevacizumab groups. 27% in the bevacizumab 7.5 mg/kg group and 16% in the bevacizumab 15 mg/kg group has got Progression Free Survival (PFS) [HR 0.75, 95% confidence interval (CI): 0.64-0.87; P = 0.0003] and by 16% in the bevacizumab 15 mg/kg group (HR 0.85, 95% CI 0.73-1.00; P = 0.0456).
Overall survival
OS at the time of the initial analysis was favorable among the bevacizumab treated groups. 25.8% and 28.2% patient has got median OS on Bevacizumab dose 15mg/kg and 7.5 mg/kg.
In the ITT population, the median OS was nevertheless the longest ever reported in NSCLC trials, 13.8 and 13.6 months in the bevacizumab 7.5 mg/kg and bevacizumab 15 mg/kg groups, respectively (HR 0.95, 95% CI 0.78-1.11; P = 0.430; HR 1.04, 95% CI 0.85-1.25; P = 0.751, respectively).
Patient Disposition
Study was conducted in Anwer Khan Modern Medical College Hospital, Dhaka, Bangladesh. Although the scrutiny of the study showed some imbalances which are along with the patient characteristics are displayed in the table below.
Table III: Selected demographic baseline characteristics

Response to Treatment
Amongthese 35 patients, some of them showed great response to Bevacizumab. Overall survival and overall response rate is significantly high.
Abbreviations: AVAiL, Avastin in Lung; HR, hazard ratio; NR, not reached; NSCLC, non-small cell lung cancer; OS, overall survival; PFS, progression-free survival; RR, response rate.
Materials and Methods
Patient's selection and evaluation:
Patients were treated at the Oncology Department of Anwer Khan Modern Medical College and Hospital, Dhaka.
Treatment Design
The Design of the treatment in this study consists of a single treatment group. Patients received a total of 6 to 8 cycle of intravenous infusion of Bevacizumab 300mg/kg and platinum based chemotherapy at every 21 days interval. There were 6 treatment regimen groups in his study. Among the groups patient number were different.
Table II: Treatment regimen
Toxicities and response Assessment
Haematological and non-haematological toxicities evaluation was conducted on day 1 of each treatment cycle.
Statistical Analysis
Patient's characteristics and therapeutic outcomes were compared in this study.
Result
Responses and toxicities of patients admitted to this renowned institute were analysed.
Progression-free survival
PFS was significantly prolonged with bevacizumab therapy. PFS benefit was maintained with longer follow-brain, or spinal cord; nosebleeds; and vaginal bleeding. If you recently coughed up blood or had serious bleeding, be sure to tell your doctor 16, 18, 19 
Toxicity profile
Bevacizumab shows well-established safety profile. In this study Grade 3 AEs are similar to the AVAiL study.
l 0.9% patients shows Haemoptysis/PH l 8.5% patients shows Hypertension l 1.2% patients shows Proteinuria l 10.0% patients shows Thromboembolism So, in conclusion Bevacizumab is the one of the important agent in NSCLC, has proven its efficacy and safety in the treatment of Bangladesh population in metastatic NSCLC.
This study recommended that Bevacizumab may be tried in other stages in lung cancer in future.
Lung cancer is a heterogeneous disease with several mutations, and it is unlikely that any one signalling pathway is driving the oncogenic behaviour of all tumours. However, bevacizumab in the treatment of chemotherapy-refractory advanced NSCLC may stimulate other similar clinical trials on
Discussion
Present scenario of NSCLC in Bangladesh is very gloomy. Patients are reporting in advance cases due to multi factors. In this advance stages (IIIB & IV), treatment outcomes is very poor not only in Bangladesh but also other part of the globe.
But newer drugs are being incorporated for the better management of these patients. One of the agent is Bevacizumab. This agent is proven efficacy in Asian population.
Considering the efficacy and toxicity profile of this agent, we conducted this study incorporating Bevacizumab with multiple chemotherapeutic schedules for Bangladeshi patients.
Our study patients were 35 where the result is mimicking many of the trials.
l 25.8% and 28.2% patient has got median OS on Bevacizumab dose 15mg/kg and 7.5 mg/kg which is similar to AVAiL study. l 13.6% and 13.4% patient has got survival beyond 12 months in first-line NSCLC on Bevacizumab dose 15mg/kg and 7.5 mg/kg respectively which is similar to AVAiL study on .
l 27% in the bevacizumab 7.5 mg/kg group and 16% in the bevacizumab 15 mg/kg group has got Progression Free Survival (PFS) which is similar to the AVAiL study.
Clinical Adverse Events
Everyone reacts differently to Bevacizumab therapy. Some patients faced life-threatening side effect, most do not.
Most serious side effects (not common, but sometimes fatal): l GI perforation: A hole that develops in your stomach or intestine. Symptoms include pain in your abdomen, nausea, vomiting, constipation, or fever 16 l Wounds that don't heal: A cut made during surgery can be slow to heal or may not fully heal. Bevacizumab should not be used for at least 28 days before or after surgery and until surgical wounds are fully healed 17 l Serious bleeding: This includes vomiting or coughing up blood; bleeding in the stomach, > an expensive treatment burdened by many sideeffects to gain a rather small clinical benefit.
Conclusion
In conclusion, the possibility of practicing a treatment with bevacizumab must be carefully analysed case by case. As a future perspective, it is important to identify patients who can really benefit from the use of this molecular-targeted drug, through identification of specific response markers and by the identification of specific patient characteristics associated with a best response to this treatment. Moreover, in light of the results of recent clinical trials, it is important to analyse new associations which could be effective and with acceptable toxicity and that can also be used in elderly patients and in therapy lines subsequent to the first.
combinations of multitargeted agents. The second generation of clinical trials on multitargeted therapy for NSCLC has begun and offers great hope of impacting the dismal prognosis of this disease.
Bevacizumab is the first targeted agent that has been demonstrated, in combination with chemotherapy, to improve outcomes over those seen with chemotherapy alone in the treatment of advanced NSCLC. The two large, phase III, randomized trials leading to these relevant results have administered bevacizumab with carboplatin plus paclitaxel and cisplatin plus gemcitabine.
However, evidence from several phase II trials has recently shown that bevacizumab also can be safely administered with other last-generation chemotherapeutic regimens, with encouraging antitumor activity results. One of the major problems related to bevacizumab therapy is the exclusion from this therapeutic option of patients with brain metastases and/or with squamous histology, which combined represent a relevant proportion of the advanced NSCLC patient population.
The topic covered in this article is still under much debate and there is no common approach to first-line treatment with bevacizumab for NSCLC. The results of pivotal studies revealed an increase of OS and of PFS. Other important aspects are the possibility of practicing a maintenance treatment, increasing the time-to-disease progression and improving the quality of life.
The use of bevacizumab is related to some adverse events, such as bleeding, thromboembolism, hypertension and proteinuria. It is contraindicated in patients with squamous histology and with recent bleeding (51), but can be used with caution in patients receiving platelet aggregation inhibitors or anti-coagulants, with bleeding or thrombophilic diathesis, and in patients with untreated brain metastases. These categories of patients, in fact, have been excluded by the majority of previous clinical trials.
Several recent trials, however, have focused on demonstrating the safety of this drug even in the categories of patients previously excluded from clinical trials. Bevacizumab leads to a gain of about two months in terms of OS. Therefore, it is not clear whether it is really appropriate to choose such
